Sequence dependence of the antitumor and toxic effects of 5-fluorouracil and cis-diamminedichloroplatinum combination on primary colon tumors in mice
- PMID: 3359558
- DOI: 10.1007/BF00262777
Sequence dependence of the antitumor and toxic effects of 5-fluorouracil and cis-diamminedichloroplatinum combination on primary colon tumors in mice
Abstract
Primary colon tumors of different sizes and malignancy, chemically induced by methylazoxymethanol in outbred CF-1 mice, were used to investigate the antitumor effects of 5-Fluorouracil (5FU) and cis-diammine-dichloroplatinum (DDP), given weekly i.v. as single agents or in combination. When single-drug chemotherapy was tested, DDP showed higher efficacy than 5FU. In fact, in two separate experiments a significant reduction (P less than 0.05) of tumor number (TN) and tumor burden was obtained by treatment with the optimal dose of DDP (4.5 mg/kg per injection) and not by that of 5FU (52 mg/kg). When the two drugs were combined (24-h interval), studies carried out on healthy mice treated weekly i.v. showed a lower toxicity with the same doses given in the sequence 5FU-DDP than in the opposite sequence. The two drugs, delivered in the sequence 5FU followed by DDP, statistically reduced the TN and total tumor burden compared to control mice (P less than 0.05). On the other hand, the same doses in the sequence DDP followed by 5FU did not attain significant tumor reduction. The sequence dependence of the activity and toxicity of the 5FU and DDP combination observed in this experimental model should be taken into account in the design of clinical trials.
Similar articles
-
The role of drug sequence in therapeutic selectivity of the combination of 5-fluorouracil and cis-platin.Sel Cancer Ther. 1989 Winter;5(4):169-77. doi: 10.1089/sct.1989.5.169. Sel Cancer Ther. 1989. PMID: 2623382
-
Effect of coadministration of selenite on the toxicity and antitumor activity of cis-diamminedichloroplatinum (II) given repeatedly to mice.Cancer Chemother Pharmacol. 1992;30(6):439-43. doi: 10.1007/BF00685594. Cancer Chemother Pharmacol. 1992. PMID: 1394800
-
Effects of 5-FU and cis-DDP combination on human colorectal tumor xenografts.Tumori. 1989 Feb 28;75(1):60-5. doi: 10.1177/030089168907500116. Tumori. 1989. PMID: 2711477
-
In vivo potentiation of 5-fluorouracil by leucovorin in murine colon carcinoma.Biomed Pharmacother. 1988;42(6):387-93. Biomed Pharmacother. 1988. PMID: 3064823 Review.
-
Clinical relevance of biochemical modulation of 5-fluorouracil.Ann Oncol. 1991 Jul;2(7):469-80. doi: 10.1093/oxfordjournals.annonc.a057994. Ann Oncol. 1991. PMID: 1911453 Review.
Cited by
-
Phase I/II study of docetaxel, cisplatin and S-1 in locally advanced, recurrent and metastatic head and neck squamous cell carcinoma.Oncol Lett. 2012 Nov;4(5):898-904. doi: 10.3892/ol.2012.846. Epub 2012 Aug 6. Oncol Lett. 2012. PMID: 23162619 Free PMC article.
-
Dose reduction without loss of efficacy for 5-fluorouracil and cisplatin combined with folinic acid. In vitro study on human head and neck carcinoma cell lines.Br J Cancer. 1991 Mar;63(3):372-7. doi: 10.1038/bjc.1991.88. Br J Cancer. 1991. PMID: 2003979 Free PMC article.
-
Synergistic induction of ICAM-1 expression by cisplatin and 5-fluorouracil in a cancer cell line via a NF-kappaB independent pathway.Br J Cancer. 1999 Jun;80(7):954-63. doi: 10.1038/sj.bjc.6690449. Br J Cancer. 1999. PMID: 10362102 Free PMC article.
-
Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo.Cancer Chemother Pharmacol. 1993;32(3):167-72. doi: 10.1007/BF00685830. Cancer Chemother Pharmacol. 1993. PMID: 8500219
-
Combination of daily 4-h infusion of 5-fluorouracil and cisplatin in the treatment of advanced head and neck squamous-cell carcinoma: a South-East European Oncology Group study.Cancer Chemother Pharmacol. 1993;31(6):489-94. doi: 10.1007/BF00685041. Cancer Chemother Pharmacol. 1993. PMID: 8453690 Clinical Trial.